Oncology Drives Most Recent Accelerated Approvals

In my most recent post on medicine approvals I explored how the HIV/AIDS crisis drove a reevaluation of what was truly essential to demonstrate a new drug’s efficacy. Allowing HIV patients to take investigational treatments meant that research into rarer conditions—which previously would never have been profitable—might now be financially worthwhile.

This post estimates the benefits of accelerated approval and how oncology medicines have become the treatment category with the most accelerated approvals.

Read the full piece here.